Its best documented pathological effects, however, concern breast carcinomas where several authors have proposed that Fra-1 might constitute a useful diagnosis marker (30) and/or a target for cancer prevention or intervention (28,31–33). This evidence concerns the gene FOSL1 and breast carcinoma.